#United States #New York #Baird Medical #microwave ablation #ATA 2025

Baird Medical Showcases Advanced Ablation Technology at 2025 American Thyroid Association Annual Meeting

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) recently made waves at the 2025 American Thyroid Association (ATA) Annual Meeting by demonstrating its state-of-the-art Microwave Ablation (MWA) technology. This innovative approach to minimally invasive procedures attracted a diverse crowd of healthcare professionals, including endocrinologists and surgeons from various regions, emphasizing the technology's global medical significance.

The conference, held in New York, provided a platform for Baird Medical to engage with over a thousand attendees who were eager to learn more about MWA. The company's exhibition booth became the focal point of the event, where in-depth technical discussions and live demonstrations captivated participants. These interactions not only showcased the clinical utility of the MWA systems but also reinforced Baird Medical's commitment to advancing thyroid disease management.

A standout moment at the conference was the session hosted in the Expo Theater, featuring Dr. Emad Kandil, a renowned expert and professor at Tulane University School of Medicine. Dr. Kandil presented compelling findings from an extensive clinical study he conducted involving over 200 MWA procedures. A particularly noteworthy aspect of his presentation was the success of MWA in a cohort of 19 patients, who had not benefited from previous Radiofrequency Ablation (RFA) treatments. This highlights MWA's potential as a crucial alternative for patients needing effective solutions.

Dr. Kandil confidently stated, "Microwave Ablation of thyroid nodules is a novel, safe, and effective method for treating appropriately selected benign and malignant thyroid nodules in both adult and pediatric populations. It can provide advantages compared to other thermal ablation techniques." His insights prompted an engaging Q&A session, illustrating the growing interest and support within the clinical community for this advanced technology.

Baird Medical's successful participation in the ATA meeting exemplifies the company's ongoing dedication to collaborating with the global medical community. They aspire to improve patient outcomes and enhance standards of care for thyroid disease, showcasing an innovative approach to patient treatment that is both effective and minimally invasive.

About Baird Medical

Baird Medical is committed to pioneering advancements in minimally invasive diagnostics and treatments. With a strong focus on researching and developing robotic surgical systems, the company aims to revolutionize the medical field. By offering innovative surgical instruments, Baird Medical is determined to enhance patient outcomes via precision technology.

Collaborating with leading academic institutions is essential to Baird Medical's mission. They strive not only to assist in surgical procedures but also to develop intelligent systems that facilitate diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has made significant inroads, having its solutions implemented in over 30 prestigious U.S. hospitals and clinics, including Johns Hopkins Hospital and Columbia University Medical Center.

Baird Medical is particularly prominent in China, leading the market in thyroid microwave ablation devices and consumables. The expansion of their minimally invasive treatment products across more than 20 countries reflects a growing acceptance of their innovative technologies worldwide.

In conclusion, Baird Medical's presence at the 2025 ATA meeting not only highlighted their technological advancements but also reinforced their commitment to the medical community, aiming to ensure patient care is both effective and progressive.